These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 11327595)

  • 21. CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-alpha]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors.
    Castro A; Abasolo MI; Gil C; Segarra V; Martinez A
    Eur J Med Chem; 2001 Apr; 36(4):333-8. PubMed ID: 11461758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Hatzelmann A; Van Klink GP; Van der Laan IJ; Sterk GJ; Thibaut U; Ulrich WR; Timmerman H
    J Med Chem; 2001 Aug; 44(16):2523-35. PubMed ID: 11472206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.
    Van der Mey M; Bommelé KM; Boss H; Hatzelmann A; Van Slingerland M; Sterk GJ; Timmerman H
    J Med Chem; 2003 May; 46(10):2008-16. PubMed ID: 12723963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors.
    Nakata A; Ogawa K; Sasaki T; Koyama N; Wada K; Kotera J; Kikkawa H; Omori K; Kaminuma O
    Clin Exp Immunol; 2002 Jun; 128(3):460-6. PubMed ID: 12067300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
    Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
    Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
    Andrés JI; Alonso JM; Díaz A; Fernández J; Iturrino L; Martínez P; Matesanz E; Freyne EJ; Deroose F; Boeckx G; Petit D; Diels G; Megens A; Somers M; Van Wauwe J; Stoppie P; Cools M; De Clerck F; Peeters D; de Chaffoy D
    Bioorg Med Chem Lett; 2002 Feb; 12(4):653-8. PubMed ID: 11844693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New imidazo(1,2-a)pyrazine derivatives with bronchodilatory and cyclic nucleotide phosphodiesterase inhibitory activities.
    Vitse O; Laurent F; Pocock TM; Bénézech V; Zanik L; Elliott KR; Subra G; Portet K; Bompart J; Chapat JP; Small RC; Michel A; Bonnet PA
    Bioorg Med Chem; 1999 Jun; 7(6):1059-65. PubMed ID: 10428374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.
    Van der Mey M; Hatzelmann A; Van der Laan IJ; Sterk GJ; Thibaut U; Timmerman H
    J Med Chem; 2001 Aug; 44(16):2511-22. PubMed ID: 11472205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase 4 isoenzyme inhibitory activity of 3-phenylxanthines and 4-pheny.
    Suzuki H; Sawanishi H; Yamamoto K; Yokogawa K; Miyamoto K
    Chem Pharm Bull (Tokyo); 2001 Feb; 49(2):188-91. PubMed ID: 11217107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors.
    Castro A; Jerez MJ; Gil C; Martinez A
    Med Res Rev; 2005 Mar; 25(2):229-44. PubMed ID: 15514991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.
    Shin HJ; Kim HJ; Kwak JH; Chun HO; Kim JH; Park H; Kim DH; Lee YS
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2313-6. PubMed ID: 12161123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.
    Whitehead JW; Lee GP; Gharagozloo P; Hofer P; Gehrig A; Wintergerst P; Smyth D; McCoull W; Hachicha M; Patel A; Kyle DJ
    J Med Chem; 2005 Feb; 48(4):1237-43. PubMed ID: 15715490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives.
    Provins L; Christophe B; Danhaive P; Dulieu J; Durieu V; Gillard M; Lebon F; Lengelé S; Quéré L; van Keulen B
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1834-9. PubMed ID: 16439121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enaminones 9. Further studies on the anticonvulsant activity and potential type IV phosphodiesterase inhibitory activity of substituted vinylic benzamides.
    Anderson AJ; Nicholson JM; Bakare O; Butcher RJ; Wilson TL; Scott KR
    Bioorg Med Chem; 2006 Feb; 14(4):997-1006. PubMed ID: 16219468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of new phosphodiesterase type 4 inhibitors.
    Ochiai H; Odagaki Y; Ohtani T; Ishida A; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Kobayashi K; Nakai H; Toda M
    Bioorg Med Chem; 2004 Oct; 12(19):5063-78. PubMed ID: 15351390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
    Buckley G; Cooper N; Dyke HJ; Galleway F; Gowers L; Gregory JC; Hannah DR; Haughan AF; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Picken CL; Runcie KA; Sabin V; Tuladhar BR; Warneck JB
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2137-40. PubMed ID: 10999488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential inhibition of multiple cAMP phosphodiesterase isozymes by isoflavones and tyrphostins.
    Nichols MR; Morimoto BH
    Mol Pharmacol; 2000 Apr; 57(4):738-45. PubMed ID: 10727520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.
    Côté B; Frenette R; Prescott S; Blouin M; Brideau C; Ducharme Y; Friesen RW; Laliberté F; Masson P; Styhler A; Girard Y
    Bioorg Med Chem Lett; 2003 Feb; 13(4):741-4. PubMed ID: 12639571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.
    Smith SJ; Cieslinski LB; Newton R; Donnelly LE; Fenwick PS; Nicholson AG; Barnes PJ; Barnette MS; Giembycz MA
    Mol Pharmacol; 2004 Dec; 66(6):1679-89. PubMed ID: 15371556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.